IL-10 production in non-small cell lung carcinoma patients is regulated by ERK, P38 and COX-2

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 3, 2012, Pages 531-544

  Patel, Swati ^a   Vetale, Shamal ^a   Teli, Pradeep ^a   Mistry, Rajesh ^a   Chiplunkar, Shubhada ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

Cyclooxygenase 2; GATA 3; IFN ; Interleukin 10; Lymphocytes; MAPK pathways; Non small cell lung carcinoma; Prostaglandin E2; Rofecoxib; T bet

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GAMMA INTERFERON; GATA3 PROTEIN, HUMAN; INTERLEUKIN 10; LACTONE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCLONAL ANTIBODY; PROSTAGLANDIN E2; PTGS2 PROTEIN, HUMAN; REACTIVE OXYGEN METABOLITE; ROFECOXIB; SULFONE; T BOX TRANSCRIPTION FACTOR; T BOX TRANSCRIPTION FACTOR TBX21; T-BOX TRANSCRIPTION FACTOR TBX21; TRANSCRIPTION FACTOR GATA 3;

ARTICLE; BIOSYNTHESIS; CELL PROLIFERATION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; LYMPHOCYTE; METABOLISM; PHYSIOLOGY; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GATA3 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; LACTONES; LUNG NEOPLASMS; LYMPHOCYTES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PRIMARY CELL CULTURE; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; SULFONES; T-BOX DOMAIN PROTEINS;

EID: 84857586238     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01329.x     Document Type: Article

References (38)

1. Patel S, Chiplunkar S. Role of cyclooxygenase-2 in tumour progression and immune regulation in lung cancer. Indian J Biochem Biophys. 2007; 44: 419-28.
2. Yang L, Yamagata N, Yadav R, et al. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest. 2003; 111: 727-35.
3. Huang M, Sharma S, Mao JT, et al. Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J Immunol. 1996; 157: 5512-20.
4. Huang M, Stolina M, Sharma S, et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res. 1998; 58: 1208-16.
5. Neuner A, Schindel M, Wildenberg U, et al. Prognostic significance of cytokine modulation in non-small cell lung cancer. Int J Cancer. 2002; 101: 287-92.
6. Marrogi AJ, Travis WD, Welsh JA, et al. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res. 2000; 6: 4739-44.
7. Shao J, Jung C, Liu C, et al. Prostaglandin E2 Stimulates the b-catenin/ T cell factor-dependent transcription in colon cancer. J Biol Chem. 2005; 280: 26565-72.
8. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998; 38: 97-120.
9. Riedl K, Krysan K, Pold M, et al. Multifaceted roles of cyclooxygenase-2 in lung cancer. Drug Resist Update. 2004; 7: 169-84.
10. Cheon H, Rho YH, Choi SJ, et al. Prostaglandin E2 augments IL-10 signaling and function. J Immunol. 2006; 177: 1092-100.
11. Harizi H, Gualde N. Pivotal role of PGE2 and IL-10 in the cross-regulation of dendritic cell-derived inflammatory mediators. Cell Mol Immunol. 2006; 3: 271-7.
12. Heuze-Vourc'h N, Zhu L, Krysan K, et al. Abnormal interleukin 10Ralpha expression contributes to the maintenance of elevated cyclooxygenase-2 in non-small cell lung cancer cells. Cancer Res. 2003; 63: 766-70.
13. Hagenbaugh A, Sharma S, Dubinett SM, et al. Altered immune responses in interleukin 10 transgenic mice. J Exp Med. 1997; 185: 2101-10.
14. Sharma S, Stolina M, Lin Y, et al. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J Immunol. 1999; 163: 5020-8.
15. Hatanaka H, Abe Y, Naruke M, et al. Significant correlation between interleukin 10 expression and vascularization through angiopoietin/TIE2 networks in non-small cell lung cancer. Clin Cancer Res. 2001; 7: 1287-92.
16. Iniguez MA, Punzon C, Fresno M. Induction of cyclooxygenase-2 on activated T lymphocytes: regulation of T cell activation by cyclooxygenase-2 inhibitors. J Immunol. 1999; 163: 111-9.
17. 2+ concentration of rat thymocytes. Jpn J Pharmacol. 1996; 71: 273-80.
18. Kao JP, Harootunian AT, Tsien RY. Photochemically generated cytosolic calcium pulses and their detection by fluo-3. J Biol Chem. 1989; 264: 8179-84.
19. Szabo SJ, Kim ST, Costa GL, et al. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell. 2000; 100: 655-69.
20. + T cells. J Immunol. 2006; 176: 3470-9.
21. Stolina M, Sharma S, Lin Y, et al. Specific inhibition of cyclooxygenase 2 restores antitumour reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol. 2000; 164: 361-70.
22. Baratelli F, Lee JM, Hazra S, et al. PGE(2) contributes to TGF-b induced T regulatory cell function in human non-small cell lung cancer. Am J Transl Res. 2010; 2: 356-67.
23. Otsuji M, Kimura Y, Aoe T, et al. Oxidative stress by tumour-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc Natl Acad Sci USA. 1996; 93: 13119-24.
24. Cemerski S, Cantagrel A, Van Meerwijk JP, et al. Reactive oxygen species differentially affect T cell receptor-signaling pathways. J Biol Chem. 2002; 277: 19585-93.
25. Nawijn MC, Dingjan GM, Ferreira R, et al. Enforced expression of GATA-3 in transgenic mice inhibits Th1 differentiation and induces the formation of a T1/ST2-expressing Th2-committed T cell compartment in vivo. J Immunol. 2001; 167: 724-32.
26. + T cell function by the transcription factor Eomesodermin. Science. 2003; 302: 1041-3.
27. Miller AT, Wilcox HM, Lai Z, et al. Signaling through Itk promotes T helper 2 differentiation via negative regulation of T-bet. Immunity. 2004; 21: 67-80.
28. Hohler T, Reuss E, Adams P, et al. A genetic basis for IFN-gamma production and T-bet expression in humans. J Immunol. 2005; 175: 5457-62.
29. Tayade C, Fang Y, Black GP, et al. Differential transcription of Eomes and T-bet during maturation of mouse uterine natural killer cells. J Leukoc Biol. 2005; 78: 1347-55.
30. Paccani SR, Boncristiano M, Ulivieri C, et al. Nonsteroidal anti-inflammatory drugs suppress T-cell activation by inhibiting p38 MAPK induction. J Biol Chem. 2002; 277: 1509\xE2\x80\x9313.
31. Tilley SL, Coffman TM, Koller BH. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest. 2001; 108: 15-23.
32. Narumiya S, FitzGerald GA. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest. 2001; 108: 25-30.
33. van der Bruggen T, Nijenhuis S, van Raaij E, et al. Lipopolysaccharide-induced tumour necrosis factor alpha production by human monocytes involves the raf-1/MEK1-MEK2/ERK1-ERK2 pathway. Infect Immun. 1999; 67: 3824-9.
34. Song GY, Chung CS, Schwacha MG, et al. Splenic immune suppression in sepsis: a role for IL-10-induced changes in P38 MAPK signaling. J Surg Res. 1999; 83: 36-43.
35. Wang S, Yang J, Qian J, et al. tumour evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood. 2006; 107: 2432-9.
36. She QB, Chen N, Bode AM, et al. Deficiency of c-Jun-NH(2)-terminal kinase-1 in mice enhances skin tumour development by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res. 2002; 62: 1343-8.
37. Dong C, Yang DD, Tournier C, et al. JNK is required for effector T-cell function but not for T-cell activation. Nature. 2000; 405: 91-4.
38. Dong C, Yang DD, Wysk M, et al. Defective T cell differentiation in the absence of Jnk1. Science. 1998; 282: 2092-5.